Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NRX Pharmaceuticals, Inc.NRXP · Entity 6523 | 10% owner | November 29, 2022 | December 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NRX Pharmaceuticals, Inc.
Report date November 29, 2022 · Filed December 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stockSEC Table I · non-derivative | Indirectby Glytech LLC | 9,634,793 |
Last balance in matching sequence
After 2022-11-30 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-11-29 · Sale · Disposed 13,730 · Balance 9,643,234 F1: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2: Held by Glytech LLC of which the Reporting Person is the sole owner. Row 2 · 2022-11-30 · Sale · Disposed 8,441 · Balance 9,634,793 F1: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2: Held by Glytech LLC of which the Reporting Person is the sole owner. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022.
F2: Held by Glytech LLC of which the Reporting Person is the sole owner.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2022 Filed Dec 1, 2022 19:29 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | Salecommon stock | 8,441 | $1.50 | $12,700.33 |
DisclosureSEC source: 0000880984-22-000017 · primary_doc.xml · nonDerivative · entry 2 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,634,793 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 19:29 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | Salecommon stock | 13,730 | $1.50 | $20,651.29 |
DisclosureSEC source: 0000880984-22-000017 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,643,234 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 19:05 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | Salecommon stock | 33,018 | $1.05 | $34,744.84 |
DisclosureSEC source: 0000880984-22-000015 · primary_doc.xml · nonDerivative · entry 2 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,656,964 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 19:05 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | Salecommon stock | 133,719 | $1.02 | $136,393.38 |
DisclosureSEC source: 0000880984-22-000015 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,689,982 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 19:40 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | Salecommon stock | 49,200 | $1.01 | $49,509.96 |
DisclosureSEC source: 0000880984-22-000014 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,823,701 F1 · kind: Sale was pursuant to the terms of a 10b5-1 trading plan established on June 13, 2022. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 17:43 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | SaleCommon Stock | 784,063 | $1.01 | $791,433.19 |
DisclosureSEC source: 0000880984-22-000009 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 9,872,901 F1 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 17:06 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GiftCommon Stock | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000880984-22-000008 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 10,656,964 F1 · shares: Shares were gifted to a charitable remainder unitrust. F2 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 20:11 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | SaleCommon Stock | 86,459 | $0.65 | $55,861.16 |
DisclosureSEC source: 0000880984-22-000007 · primary_doc.xml · nonDerivative · entry 3 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 12,656,964 F1 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 20:11 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | SaleCommon Stock | 115,657 | $0.67 | $76,946.60 |
DisclosureSEC source: 0000880984-22-000007 · primary_doc.xml · nonDerivative · entry 2 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 12,743,423 F1 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:11 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | SaleCommon Stock | 243,596 | $0.70 | $171,101.83 |
DisclosureSEC source: 0000880984-22-000007 · primary_doc.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Glytech LLC Disclosed balance after: 12,859,080 F1 · ownership.nature: Held by Glytech LLC of which the Reporting Person is the sole owner. Read SEC document |
| July 16, 2021 Filed Nov 2, 2021 16:06 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GiftCommon Stock | 434,594 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-003505 · es210197024_4-javittd.xml · nonDerivative · entry 2 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Glytech LLC Disclosed balance after: 13,102,676 F1 · price: Irrevocable gift by way of transfer to certain trusts established for the benefit of the Reporting Person's immediate family members. Neither the Reporting Person nor Glytech LLC received any compensation in respect of such transfers. Upon completion of such transfers, both the Reporting Person and Glytech LLC ceased to have any beneficial ownership or other interest in the shares subject to the transfers. F2 · ownership.nature: Held by Glytech, LLC of which the Reporting Person is the sole owner. Read SEC document |
| July 16, 2021 Filed Nov 2, 2021 16:06 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GiftCommon Stock | 434,594 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-003505 · es210197024_4-javittd.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Glytech LLC Disclosed balance after: 13,537,270 F1 · price: Irrevocable gift by way of transfer to certain trusts established for the benefit of the Reporting Person's immediate family members. Neither the Reporting Person nor Glytech LLC received any compensation in respect of such transfers. Upon completion of such transfers, both the Reporting Person and Glytech LLC ceased to have any beneficial ownership or other interest in the shares subject to the transfers. F2 · ownership.nature: Held by Glytech, LLC of which the Reporting Person is the sole owner. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:48 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock | 13,971,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-001944 · es210157189_4-javittd.xml · nonDerivative · entry 1 Javitt Daniel C. · CIK 0001864534 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 13,971,864 F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement). F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger. F3 · ownership.nature: Held by Glytech, LLC of which the Reporting Person is the sole owner. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.